157 related articles for article (PubMed ID: 37458957)
1. Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma.
Song F; Zhang Q; Lu X; Xu T; Hu Q; Hu X; Fan W; Zhang Y; Huang P
J Physiol Biochem; 2023 Nov; 79(4):757-770. PubMed ID: 37458957
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma.
Hu F; Deng X; Yang X; Jin H; Gu D; Lv X; Wang C; Zhang Y; Huo X; Shen Q; Luo Q; Zhao F; Ge T; Zhao F; Chu W; Shu H; Yao M; Fan J; Qin W
Oncogene; 2015 Dec; 34(49):6007-17. PubMed ID: 25745995
[TBL] [Abstract][Full Text] [Related]
3. Rab11-FIP3 and FIP4 interact with Arf6 and the exocyst to control membrane traffic in cytokinesis.
Fielding AB; Schonteich E; Matheson J; Wilson G; Yu X; Hickson GR; Srivastava S; Baldwin SA; Prekeris R; Gould GW
EMBO J; 2005 Oct; 24(19):3389-99. PubMed ID: 16148947
[TBL] [Abstract][Full Text] [Related]
4. High Rab11-FIP4 expression predicts poor prognosis and exhibits tumor promotion in pancreatic cancer.
He Y; Ye M; Zhou L; Shan Y; Lu G; Zhou Y; Zhong J; Zheng J; Xue Z; Cai Z
Int J Oncol; 2017 Feb; 50(2):396-404. PubMed ID: 28035375
[TBL] [Abstract][Full Text] [Related]
5. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
6. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.
Chang TS; Chen CL; Wu YC; Liu JJ; Kuo YC; Lee KF; Lin SY; Lin SE; Tung SY; Kuo LM; Tsai YH; Huang YH
PLoS One; 2016; 11(2):e0149897. PubMed ID: 26919045
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
8. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
9. Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.
Liu B; Fang X; Kwong DL; Zhang Y; Verhoeft K; Gong L; Zhang B; Chen J; Yu Q; Luo J; Tang Y; Huang T; Ling F; Fu L; Yan Q; Guan XY
J Exp Clin Cancer Res; 2022 May; 41(1):182. PubMed ID: 35610614
[TBL] [Abstract][Full Text] [Related]
10. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
Chen G; Wang Y; Zhao X; Xie XZ; Zhao JG; Deng T; Chen ZY; Chen HB; Tong YF; Yang Z; Ding XW; Guo PY; Yu HT; Wu LJ; Zhang SN; Zhu QD; Li JJ; Shan YF; Yu FX; Yu ZP; Xia JL
J Exp Clin Cancer Res; 2021 Jun; 40(1):218. PubMed ID: 34193219
[TBL] [Abstract][Full Text] [Related]
11. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
12. HCMV-encoded glycoprotein M (UL100) interacts with Rab11 effector protein FIP4.
Krzyzaniak MA; Mach M; Britt WJ
Traffic; 2009 Oct; 10(10):1439-57. PubMed ID: 19761540
[TBL] [Abstract][Full Text] [Related]
13. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
14. Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.
Jiang L; Shan J; Shen J; Wang Y; Yan P; Liu L; Zhao W; Xu Y; Zhu W; Su L; Chen J; Cheng F; Yao H; Xu H; Qian C; Liang Z
Oncotarget; 2016 Jun; 7(24):36814-36828. PubMed ID: 27167111
[TBL] [Abstract][Full Text] [Related]
15. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
Chen J; Li H; Zhang B; Xiong Z; Jin Z; Chen J; Zheng Y; Zhu X; Zhang S
Liver Int; 2022 Nov; 42(11):2562-2576. PubMed ID: 36017822
[TBL] [Abstract][Full Text] [Related]
16. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
[TBL] [Abstract][Full Text] [Related]
17. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
18. Rab11-FIP4 is predominantly expressed in neural tissues and involved in proliferation as well as in differentiation during zebrafish retinal development.
Muto A; Arai K; Watanabe S
Dev Biol; 2006 Apr; 292(1):90-102. PubMed ID: 16457799
[TBL] [Abstract][Full Text] [Related]
19. Rab11-FIP4 interacts with Rab11 in a GTP-dependent manner and its overexpression condenses the Rab11 positive compartment in HeLa cells.
Wallace DM; Lindsay AJ; Hendrick AG; McCaffrey MW
Biochem Biophys Res Commun; 2002 Dec; 299(5):770-9. PubMed ID: 12470645
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
